Sun Pharmaceutical Industries Limited, the largest drug maker in India in terms of market value, witnessed a fall in its share price due to an import alert placed on the company by the FDA in the United States. These import restrictions to the United States have been attributed due to non-adherence of manufacturing guidelines in one plant.
GlaxoSmithKline PLC has announced that it may file global regulatory approval for a drug for severe asthma later this year, after it released positive results for two late-stage studies on Wednesday. The first study found that after using mepolizumab patients with a severe and often crippling form of a disease called eosinophilic asthma sought immense reduction in the frequency of attacks.
In order to address the quality concerns with generic drug makers, the head of the U. S. Food and Drug Administration said she will visit India. There are also plans to discuss the expansion of inspection carried out overseas in order address the country's growing role in producing medicines sold in the U. S.